Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and Development of the Quininib Series of Ocular Drugs.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics - 1 Jan 2000

Mahon Niamh, Slater Kayleigh, O'Brien Justine, Alvarez Yolanda, Reynolds Alison, Kennedy Breandán

Abstract excerpt

The quininib series is a novel collection of small-molecule drugs with antiangiogenic, antivascular permeability, anti-inflammatory, and antiproliferative activity. Quininib was initially identified as a drug hit during a random chemical library screen for determinants of developmental ocular angiogenesis in zebrafish. To enhance drug efficacy, novel quininib analogs were designed by applying medicinal chemistry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Diabetic Retinopathy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Development

Share to Eye Neoplasms

Share to Phenols

Share to Quinolines

Share to Retinal Diseases

Share to Retinal Neovascularization

Source

Identifiers

PMID: 35089801
DOI: 10.1089/jop.2021.0074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and Development of the Quininib Series of Ocular Drugs.PMID 35089801Read ↗

High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma CellsSemantic proximity Read ↗

1,4-dihydroxy Quininib Attenuates Growth of Colorectal Cancer Cells and Xenografts and Regulates the TIE-2 Signaling Pathway in Patient TumoursSemantic proximity Read ↗

In vivoscreening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systemsSemantic proximity Read ↗

A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular NeovascularizationSemantic proximity Read ↗

Small molecule screen for compounds that affect vascular development in the zebrafish retina.Semantic proximity Read ↗

A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylationSemantic proximity Read ↗

The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal diseaseSemantic proximity Read ↗

Orthogonal Drug Pooling Enhances Phenotype-based Discovery of Ocular Anti-angiogenic Drugs in Zebrafish LarvaeSemantic proximity Read ↗

Topical Administration of the Kappa Opioid Receptor Agonist Nalfurafine Suppresses Corneal Neovascularization and InflammationSemantic proximity Read ↗

A novel retinoic acid drug, EYE-502, inhibits choroidal neovascularization by targeting endothelial cells and pericytesSemantic proximity Read ↗

Mechanistic Insights into 2-5(H)-Furanone-Mediated Inhibition of Angiogenesis Using HUVECs and Zebrafish ModelsSemantic proximity Read ↗

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.